CytomX Therapeutics Inc. (CTMX) Rating Lowered to Hold at Zacks Investment Research
CytomX Therapeutics Inc. (NASDAQ:CTMX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. “
Shares of CytomX Therapeutics (NASDAQ:CTMX) opened at 11.31 on Friday. CytomX Therapeutics has a 12-month low of $9.10 and a 12-month high of $24.68. The firm has a 50-day moving average price of $13.13 and a 200 day moving average price of $11.73. The stock’s market cap is $411.71 million.
In other news, Director Ix L.P. Canaan sold 86,270 shares of the stock in a transaction on Monday, November 14th. The stock was sold at an average price of $11.16, for a total value of $962,773.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.70% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in CytomX Therapeutics during the third quarter valued at about $117,000. American International Group Inc. raised its stake in shares of CytomX Therapeutics by 165.7% in the second quarter. American International Group Inc. now owns 11,759 shares of the company’s stock valued at $120,000 after buying an additional 7,333 shares during the period. Wells Fargo & Company MN raised its stake in shares of CytomX Therapeutics by 253.6% in the third quarter. Wells Fargo & Company MN now owns 7,808 shares of the company’s stock valued at $122,000 after buying an additional 5,600 shares during the period. Nationwide Fund Advisors raised its stake in shares of CytomX Therapeutics by 146.8% in the second quarter. Nationwide Fund Advisors now owns 12,925 shares of the company’s stock valued at $132,000 after buying an additional 7,688 shares during the period. Finally, BlackRock Inc. raised its stake in shares of CytomX Therapeutics by 23.2% in the third quarter. BlackRock Inc. now owns 9,344 shares of the company’s stock valued at $146,000 after buying an additional 1,759 shares during the period. 51.59% of the stock is owned by institutional investors.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.